Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Earnings for Ipca Laboratories Limited (IPCALAB.NS)
Earnings in 2023 (TTM): $100.28 M
According to Ipca Laboratories Limited's latest financial reports the company's current earnings (TTM) are $100.28 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ipca Laboratories Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $100.28 M | $65.14 M |
| 2022 | $88.69 M | $56.09 M |
| 2021 | $135.16 M | $105.21 M |
| 2020 | $164.38 M | $135.67 M |
| 2019 | $87.93 M | $72.16 M |
| 2018 | $65.03 M | $52.94 M |
| 2017 | $34.57 M | $28.49 M |
| 2016 | $32.17 M | $24.13 M |
| 2015 | $13.72 M | $11.51 M |
| 2014 | $42.97 M | $30.84 M |
| 2013 | $75.04 M | $56.91 M |
| 2012 | $54.06 M | $38.6 M |
| 2011 | $43.36 M | $32.97 M |
| 2010 | $40.54 M | $31.28 M |
| 2009 | $31.69 M | $24.44 M |
| 2008 | $14.08 M | $12 M |
| 2007 | $20.86 M | $16.18 M |
| 2006 | $18.36 M | $15.02 M |
| 2005 | $8.87 M | $7.32 M |
| 2004 | $11.2 M | $8.82 M |